View Older Stories View More Recent Stories

Nov 3, 2023 04:05PM Sensei Biotherapeutics (SNSE) Reports Favorable Clinical Data for SNS-101
Nov 3, 2023 04:05PM Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting
Nov 1, 2023 07:30AM Sensei Biotherapeutics (SNSE) Appoints Stephanie Krebs as Chief Business Officer
Nov 1, 2023 07:30AM Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer
Oct 25, 2023 09:05AM Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting
Oct 23, 2023 07:30AM Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023
Sep 27, 2023 07:30AM Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®
Sep 21, 2023 07:31AM Sensei Biotherapeutics (SNSE) Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action
Sep 21, 2023 07:30AM Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immun
Sep 13, 2023 07:30AM Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, a
Aug 30, 2023 07:30AM Sensei Biotherapeutics to Participate in Upcoming Investor Conferences
Aug 3, 2023 07:30AM Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
Aug 2, 2023 07:30AM Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference
Jun 13, 2023 07:30AM Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101’s Potential as a Transformative Treatment Option for Patients with Solid Tumors”
Jun 1, 2023 07:30AM Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors
May 31, 2023 07:30AM Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference
May 9, 2023 07:30AM Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
Apr 20, 2023 07:30AM Sensei Biotherapeutics (SNSE) Announces FDA Clearance of Phase 1 Study of SNS-101
Apr 20, 2023 07:30AM Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody
Apr 18, 2023 04:16PM Sensei Biotherapeutics (SNSE) Presents New Preclinical Data on SNS-103
Apr 18, 2023 04:05PM Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
Apr 13, 2023 07:30AM Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference
Mar 30, 2023 07:30AM Sensei Biotherapeutics to Participate in Cantor Fitzgerald’s Future of Oncology Virtual Symposium
Mar 28, 2023 07:30AM Sensei Biotherapeutics Reports Full Year 2022 Financial Results and Recent Business Highlights
Mar 21, 2023 07:32AM Sensei Biotherapeutics (SNSE) Submits IND for SNS-101
Mar 21, 2023 07:30AM Sensei Biotherapeutics Announces Submission of Investigational New Drug (IND) Application for SNS-101, a Conditionally Active VISTA-Blocking Antibody
Mar 14, 2023 04:35PM Sensei Biotherapeutics to Present New Preclinical Data for SNS-103, a Conditionally Active Monoclonal Antibody Targeting ENTPDase1 (CD39), at the American Association for Cancer Research (AACR) Annual
Mar 7, 2023 05:15PM Sensei Biotherapeutics Adopts Stockholder Rights Agreement
Mar 6, 2023 07:30AM Sensei Biotherapeutics to Participate in Oppenheimer’s 33rd Annual Healthcare Conference
Feb 21, 2023 07:30AM Sensei Biotherapeutics (SNSE) Presents Preclinical Data for SNS-101
Feb 21, 2023 07:30AM Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
Feb 16, 2023 07:30AM Sensei Biotherapeutics to Participate in Citi’s 2023 Virtual Oncology Leadership Summit
Feb 14, 2023 07:30AM Sensei Biotherapeutics to Present New Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Keystone Symposia on Next Generation Antibody Therapeutics
Feb 6, 2023 07:31AM Sensei Biotherapeutics (SNSE) Signs CRAD with NCI to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocking Antibody
Feb 6, 2023 07:30AM Sensei Biotherapeutics Signs Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) to Expand Development Plan for SNS-101, a Conditionally Active VISTA-blocki
Jan 5, 2023 07:31AM Sensei Biotherapeutics (SNSE) Enter Supply Agreement with Regeneron for Phase 1/2 Trial of SNS-101
Jan 5, 2023 07:30AM Sensei Biotherapeutics Announces Clinical Supply Agreement with Regeneron for Phase 1/2 Clinical Trial Evaluating SNS-101, a Conditionally Active VISTA-blocking Antibody, in Combination with Libtayo®
Dec 8, 2022 07:31AM Sensei Biotherapeutics (SNSE) Provides Update on Strategic Priorities
Dec 8, 2022 07:30AM Sensei Biotherapeutics Provides Update on Strategic Priorities
Nov 22, 2022 07:30AM Sensei Biotherapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nov 21, 2022 07:30AM Sensei Biotherapeutics (SNSE) Collaborates with Washington University, St. Louis for Development of SNS-101
Nov 21, 2022 07:30AM Sensei Biotherapeutics Announces Collaboration with Washington University, St. Louis to Support Development of SNS-101, a Conditionally Active VISTA-blocking Antibody
Nov 10, 2022 09:00AM Sensei Biotherapeutics Presents Preclinical Data at the 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 8, 2022 07:30AM Sensei Biotherapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
Nov 7, 2022 07:30AM Sensei Biotherapeutics to Host Virtual Key Opinion Leader Webinar, “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint”
Nov 2, 2022 07:30AM Sensei Biotherapeutics to Participate in the 13th Annual Jefferies Global Healthcare Conference
Oct 5, 2022 08:05AM Sensei Biotherapeutics to Present New Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Sep 30, 2022 04:06PM Sensei Biotherapeutics (SNSE) Presents Preclinical Data for SNS-101
Sep 30, 2022 04:05PM Sensei Biotherapeutics Presents Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translati
Sep 21, 2022 04:05PM Sensei Biotherapeutics to Present Preclinical Data for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Transla
View More Recent Stories View Older Stories